Log In
BCIQ
Print this Print this
 

maribavir (SHP620)

Also known as: Camvia (1263W94)

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionOral anticytomegalovirus (CMV) agent
Molecular Target Not available
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationCytomegalovirus (CMV)
Indication DetailsFirst-line treatment of asymptomatic cytomegalovirus (CMV) in transplant recipients.; Prevent cytomegalovirus (CMV) infection in allogeneic bone marrow and solid organ transplant patients; Prevent cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients; Prevent cytomegalovirus (CMV) infection in stem cell transplant patients; Prevent cytomegalovirus (CMV) viremia and disease in at risk populations; Treat and prevent cytomegalovirus (CMV) in transplant patients; Treat cytomegaloviral (CMV) disease in patients with impaired cell mediated immunity; Treat cytomegalovirus (CMV) infection in hematopoietic stem cell or solid organ transplant recipients; Treat resistant/refractory cytomegalovirus (CMV) infection in transplant recipients
Regulatory Designation U.S. - Orphan Drug (Prevent cytomegalovirus (CMV) viremia and disease in at risk populations);
EU - Orphan Drug (Prevent cytomegalovirus (CMV) viremia and disease in at risk populations)
PartnerShire plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today